Board and Management
Board of Directors
Åsa Riisberg is formerly a Partner and Member of the Extended Executive Committee at EQT Partners AB. She held various leadership roles during her 20 year tenure at EQT, including Global Head of Healthcare Sector, Member of the Partners Committee and various other roles. Prior to joining EQT, Mrs Riisberg was an Associate at Texas Pacific Group (UK) and an Analyst at Morgan Stanley (UK).
She currently holds board memberships in Vifor Pharma AG (Member of the Board and Chair of Audit Committee), Netcompany AS (Member of the Board and Chair of Audit Committee), F-Secure Oy, Bonnier Capital, Bonnier News, Cinder Invest and Dagens Nyheter.
She holds a M.Sc. in Financial Economics and Business Administration from Stockholm School of Economics.
Prof. Uhlén is a co-founder of Atlas Antibodies AB. He is a Professor of Biotechnology at the Royal Institute of Technology in Stockholm and Program Director of the Human Protein Atlas project. Prof. Uhlén is a member of the Board of Directors of Novozymes A/S, Affibody AB, ScandiBio Therapeutics AB, ScandiEdge Therapeutics AB, and The Antibodypedia AB.
Dr. Ljungqvist is chairperson of SwedenBIO, Department of Biotechnology at the Royal Academy of Engineering Sciences and board member of BioArctic AB, BioLamina AB, NorthX Biologics AB, Genovis AB and Arocell AB. Previously she was CEO of Testa Center at GE Healthcare Life Sciences/Cytiva, President and CEO of GE Nordics and head of R&D BioProcess GE Healthcare Life Sciences. Other positions she has held include CEO of IMEA, VP Biopharmceutical Contract Manufacturing Organization at Biovitrum and project management positions with Pharmacia Corp & Pharmacia & Upjohn. She holds a Ph.D. in Biochemistry from the Royal Institute of Technology in Stockholm.
Ms. Kores is Investment Professional at Patricia Industries. She is also board member at Advanced Instruments and Chair at mumbaistockholm. Previously she was Board member at Doktor24, Memira and deputy board member at Aleris. Prior to joining Patricia Industries, she was an analyst at Goldman Sachs. She holds a M.Sc. in Financial Economics and Business Administration from Stockholm School of Economics.
Gavin Wood, currently the Chief Financial Officer of Adaptimmune Therapeutics Plc (NASDAQ:ADAP), a leader in TCR T-cell therapy, has over 17 years of experience from senior roles within the life sciences sector, focusing on financial operations and strategy. Prior to joining Adaptimmune, Gavin served as the Chief Financial Officer at Abcam Plc (LSE:ABC) and Executive Vice President and Chief Financial Officer at Affymetrix Inc. (NASDAQ:AFFX)..
Dr. Christian Eberle comes most recently from the role as CEO of evitria, part of the Atlas Antibodes group. During his career, Christian Eberle has accumulated broad experience in business strategy as well as in research, development and manufacturing within the pharmaceutical and biotechnology industry, including CDMO companies.
Zacharias Rudberg is an investment professional at Patricia Industries where he also supports Permobil. Prior to joining Patricia Industries, Zacharias worked at Bain & Company in Stockholm. He holds an M.Sc. in Industrial Engineering and Management from the Royal Institute of Technology, partly completed at the University of Illinois.
Atlas Group Leadership team
Peter Ulvskjold joined Atlas Antibodies from his role as Chief Transformation Officer at ConvaTec. Prior to that, Peter worked 17 years in Novo Nordisk holding various leadership positions globally. He has extensive experience in building organizations, expanding business and driving a profitable growth journey in both the MedTech and pharmaceutical industry. Peter Holds and M.Sc. in Economics and Business Administration from Aarhus University.
Mr. Tristram has over 20 years’ experience in the in vitro diagnostics field having started with developing monoclonal antibodies for tissue diagnostics at Novocastra Laboratories. Acquired by Vision BioSystems, he subsequently went on to roles in sales and marketing supporting a rapidly growing business globally with their Bond automated IHC/ISH platform. This was in turn acquired by Danaher and incorporated into Leica Biosystems. Mr. Tristram then created and headed an innovations group at their Advanced Staining site in Newcastle upon Tyne, looking at new technologies and diagnostic applications. In 2012 he left and started consulting, with which he funded and co-founded HistoCyte Laboratories developing and commercialising a range of IHC/ISH cell-based controls.
Ingela Hofverberg joined Atlas Antibodies from her role as Head of Lean & Transformation in SAS where she spent the last 6 years driving operational excellence through people and culture. Ingela is a highly experienced, driven, and passionate leader with more than 15 years of working with business transformation whereof 10 of them in Scania in various roles and parts of the organisation. Ingela has designed and implemented management systems and structures founded on Lean values and principles. Ingela holds a M.Sc. in Economics and Business Administration from Stockholm School of Economics partly completed at Darden Business School at University of Virginia.
Vendela joined Atlas Antibodies from her role as Nordic Head of Marketing and Communication at The Adecco Group. Before building the first Nordic marketing function at The Adecco Group, she built Digital Sales and Marketing for the Swedish organization. She has a background in management consulting and from leading roles in digital marketing companies such as Rocket Internet. Vendela holds a double M.Sc. in Economics and Management of Innovation from Copenhagen Business School and Bocconi, partly completed at Marshall School of Business at the University of Southern California.
Monia Stavrum joined Atlas Antibodies in February 2021. She has extensive experience from more than 25 years in different specialist and management roles within HR, driving and leading transformation, improvements, and development from different Industries. Ms. Stavrum studied PAO at Stockholm University.
Filippa Stenberg is on a one-year secondment from her role as Investment Manager at Investor AB, where she is responsible for Investor’s listed Healthcare companies. Prior to joining Investor in 2012, she worked as an analyst at Swedbank Equity Capital Markets for a couple of years. Filippa is also a member of the Board of Directors of the listed biopharmaceutical company Swedish Orphan Biovitrum (Sobi). She holds a M.Sc. in Accounting and Financial Management from Stockholm School of Economics.
Atlas Antibodies Management team
Kia Frenssen joined Atlas Antibodies in 2021. She has extensive experience from leading roles within Supply Chain, Production and Quality Assurance from Astra, AstraZeneca and APL, Apotek Produktion och Laboratorier AB.
Ms. Frenssen holds a M.Sc in Pharmacy.
Catrine Siöberg joined Atlas Antibodies in 2022 to lead the Research and Development department. She holds a PhD in Medical Biochemistry at the Karolinska Institute and has long experience in the protein research field. Catrine has a strong innovation background and was one of the key-players in developing and commercializing the CETSA® method. She has extensive experience in building and leading research teams and as Chief Operating Officer at Pelago Bioscience AB, she established and scaled up a CRO business delivering research projects to the Pharma and Biotech industry.